BidaskClub upgraded shares of REDHILL BIOPHAR/S (NASDAQ:RDHL) from a hold rating to a buy rating in a research note published on Saturday morning, BidAskClub reports.

A number of other brokerages have also commented on RDHL. BTIG Research assumed coverage on REDHILL BIOPHAR/S in a research report on Friday, September 11th. They issued a buy rating and a $26.00 price objective for the company. Zacks Investment Research lowered REDHILL BIOPHAR/S from a hold rating to a sell rating in a research report on Saturday, August 15th. Finally, ValuEngine upgraded REDHILL BIOPHAR/S from a hold rating to a buy rating in a report on Tuesday, September 1st. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $14.94.

Shares of RDHL stock opened at $10.76 on Friday. The stock has a 50-day moving average price of $8.18 and a 200 day moving average price of $6.72. The company has a quick ratio of 1.57, a current ratio of 1.70 and a debt-to-equity ratio of 2.41. The firm has a market cap of $379.51 million, a price-to-earnings ratio of -6.99 and a beta of 1.74. REDHILL BIOPHAR/S has a 12 month low of $3.26 and a 12 month high of $10.96.

REDHILL BIOPHAR/S (NASDAQ:RDHL) last announced its quarterly earnings data on Thursday, August 13th. The biotechnology company reported ($0.45) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.31). The firm had revenue of $20.90 million during the quarter, compared to analyst estimates of $20.52 million. REDHILL BIOPHAR/S had a negative return on equity of 135.90% and a negative net margin of 219.39%. Sell-side analysts predict that REDHILL BIOPHAR/S will post -0.77 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Ingalls & Snyder LLC boosted its holdings in REDHILL BIOPHAR/S by 7.1% during the second quarter. Ingalls & Snyder LLC now owns 20,985 shares of the biotechnology company’s stock worth $141,000 after buying an additional 1,385 shares during the last quarter. Bank of America Corp DE boosted its holdings in REDHILL BIOPHAR/S by 67.7% during the second quarter. Bank of America Corp DE now owns 5,155 shares of the biotechnology company’s stock worth $35,000 after buying an additional 2,081 shares during the last quarter. D.A. Davidson & CO. boosted its holdings in REDHILL BIOPHAR/S by 50.0% during the second quarter. D.A. Davidson & CO. now owns 16,500 shares of the biotechnology company’s stock worth $111,000 after buying an additional 5,500 shares during the last quarter. ETF Managers Group LLC boosted its holdings in REDHILL BIOPHAR/S by 9.8% during the first quarter. ETF Managers Group LLC now owns 61,935 shares of the biotechnology company’s stock worth $271,000 after buying an additional 5,504 shares during the last quarter. Finally, Ironwood Investment Management LLC lifted its holdings in shares of REDHILL BIOPHAR/S by 50.5% during the 1st quarter. Ironwood Investment Management LLC now owns 27,311 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 9,164 shares in the last quarter. Hedge funds and other institutional investors own 19.71% of the company’s stock.

REDHILL BIOPHAR/S Company Profile

RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.

Featured Story: What is a put option?

Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.